Aris Mining Corporation (Aris Mining or the Company) (TSX: ARIS) (NYSE-A:ARMN) announces that, as disclosed by S&P Dow Jones Indices on September 5, 2025, the Company's common shares will be added to the S&P/TSX Composite Index (visit: S&P/TSX Composite Index | S&P Dow Jones Indices) prior to the open of trading on Monday, September 22, […]
Netskope, a leader in modern security and networking for the cloud and AI era, today announced that it has launched the roadshow for its proposed initial public offering of Class A common stock. Netskope has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) to offer 47,800,000 shares
CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the
Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European Union GlobeNewswire September 08, 2025 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 (GLOBE NEWSWIRE) — Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative
Type C FDA Meeting Requested, Update Expected by Year-End 2025 Atossa Therapeutics, Inc. (Nasdaq: ATOS; “Atossa” or the “Company”) announced today it has requested a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss a regulatory strategy aimed at accelerating development of low-dose (Z)-endoxifen for breast cancer risk reduction. Atossa is
Acclaimed breast surgeon to lead integrated program focused on coordinated cancer care for women in South Jersey AtlantiCare, southern New Jersey's largest and award-winning health system, has appointed nationally recognized breast surgical oncologist Dr. Kay Yoon-Flannery, as Chief of Women's Oncology at the AtlantiCare Cancer Care Institute. https://mma.prnewswire.com/media/2767139/Yoon_Flannery_Kay_DO__wc_2025_13.jpg A fellowship-trained breast surgical oncologist known for
New hire to expand issuer-focused research and AI-driven disclosure; accelerate product innovation and client impact DragonGC, the AI platform for corporate governance, compliance, and shareholder communications, today announced the appointment of Emily Drazan Chapman as Legal AI Architect. In this role, Chapman will expand DragonGC's governance research and shareholder communications content, partnering with in-house counsel
AppYea Inc. (OTCQB: APYP) today issued a development update on its TechLott-powered blockchain results engine, a game-agnostic layer for gaming, virtual horse racing, video games, and sweepstakes. The Company remains on track to complete the adaptation of the platform to new and additional applications during Q4 2025. Highlights – Blockchain Infrastructure Catalyst — Blockchain infrastructure
Integration with Paze gives Nuvei merchants access to a fast, tokenized checkout, helping drive higher conversion, and additional security at checkout through tokenization because actual card numbers aren't shared with merchants Nuvei today announced a partnership with Early Warning Services, to bring Paze, a fast and convenient online checkout solution available in the U.S., to
Article published in European Journal of Surgical Oncology focused on cosmetic outcomes and patient satisfaction reports 95% of patients were very satisfied or satisfied with thermal ablation Article published in Radiology demonstrated that cryoablation with ProSense® achieved the highest complete ablation rate compared to alternatives with no adverse events IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure”,